Durability and Safety of CCH With Two Different Injection Techniques in Cellulite With Laxity

Completed

Conditions studied: Cellulite, Laxity; Skin, Edematous Fibrosclerotic Panniculopathy

In brief

All participants who completed the EN3835-224 study will be invited to participate in this observational study to evaluate long term durability of response and safety.

Key facts

Study ID

NCT05249257

Run by

Endo USA Inc., a Keenova Therapeutics Company

People needed

20

Starts

2022-01-25

Expected to finish

2022-09-12

Last updated by the study team

2023-01-19

Who can join

Age: 18 and older, up to 55. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Have participated in and completed study EN3835-224 (parent study).
• Be willing and able to cooperate with the requirements of the study.

You may not qualify if…

• Has received any collagenase treatments (eg, Santyl® Ointment) at any time since
• Has had any surgery, invasive procedure (eg, liposuction), injectable treatment (eg, KYBELLA®) or any similar treatment in the area treated during the EN3835-224 study since the completion of that study.
• Has any other conditions that, in the investigator's opinion, might indicate the participant to be unsuitable for the study

Where it is running

• Endo Clinical Trial Site #2 — Coral Gables, Florida, United States
• Endo Clinical Trial Site #3 — Metairie, Louisiana, United States
• Endo Clinical Trial Site #1 — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.